Barclays PLC Acquires 21,179 Shares of Biodesix, Inc. (NASDAQ:BDSX)

Barclays PLC boosted its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 1,140.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,036 shares of the company’s stock after buying an additional 21,179 shares during the period. Barclays PLC’s holdings in Biodesix were worth $41,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. CVI Holdings LLC bought a new stake in shares of Biodesix in the second quarter valued at about $59,000. Perceptive Advisors LLC bought a new stake in Biodesix in the 2nd quarter valued at approximately $3,326,000. Perkins Capital Management Inc. grew its stake in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after acquiring an additional 310,000 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix in the third quarter valued at approximately $262,000. Finally, Geode Capital Management LLC lifted its position in shares of Biodesix by 50.7% in the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after purchasing an additional 270,724 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

Biodesix Stock Up 14.4 %

Biodesix stock opened at $1.03 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 1-year low of $0.86 and a 1-year high of $2.21. The company has a fifty day simple moving average of $1.33 and a 200 day simple moving average of $1.55. The company has a market cap of $149.83 million, a P/E ratio of -2.64 and a beta of 1.10.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Friday, November 1st. The company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The company had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. During the same quarter last year, the firm posted ($0.12) EPS. Research analysts anticipate that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Biodesix

In other Biodesix news, Director Jack W. Schuler acquired 200,000 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was purchased at an average price of $1.17 per share, with a total value of $234,000.00. Following the acquisition, the director now directly owns 31,094,935 shares of the company’s stock, valued at approximately $36,381,073.95. This trade represents a 0.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman John Patience bought 75,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were acquired at an average price of $1.38 per share, for a total transaction of $103,500.00. Following the transaction, the chairman now owns 2,153,298 shares in the company, valued at approximately $2,971,551.24. This represents a 3.61 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 315,000 shares of company stock valued at $393,500. 69.20% of the stock is currently owned by corporate insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.